Yu Dechao
{{Orphan|date=September 2019}}
{{family name hatnote|Yu|lang=Chinese}}
Yu Dechao ({{zh|c=俞德超|p=}}, born February 4, 1964), also known as Michael Yu,{{cite book|title=Macular Degeneration: New Insights for the Healthcare Professional: 2013 Edition: ScholarlyBrief|url=https://books.google.com/books?id=vbpyWEizciAC&pg=PA22|date=22 July 2013|publisher=ScholarlyEditions|isbn=978-1-4816-5391-6|pages=22–}} is the founder and CEO of the Chinese pharmaceutical company Innovent Biologics.{{cite news|url=https://www.bloomberg.com/news/articles/2018-01-15/capital-group-said-to-eye-pre-ipo-stake-in-china-biotech-unicorn|title=Capital Group Eyes Pre-IPO Stake in China Biotech Unicorn|work=Bloomberg News|access-date=15 January 2018}} He received a PhD degree in Genetics from the Chinese Academy of Sciences{{cite news|url=http://alumni.cas.cn/yyfc/201512/t20151221_4500220.html|title=Michael Yu:High Quality Drugs Should be Affordable to Ordinary People|work=Chinese Academy of Sciences|access-date=1 December 2015}} and completed post-doctoral training in pharmaceutical chemistry at the UCSF.{{cite news|url=http://www.chinadaily.com.cn/kindle/2017-04/20/content_29012539.htm|title=Recruitment program a magnet for talent|date=Apr 20, 2017|work=China Daily}} As an inventor and owner of more than 60 patents (including 38 U.S. patents), Yu established Innovent Biologics in 2011.{{cite news|url=https://www.thestar.com.my/business/business-news/2018/01/17/capital-group-eyeing-stake-in-china-biotech-unicorn-innovent/|title=Capital Group eyeing stake in China biotech unicorn|work=The Star (Malaysia)|access-date=17 January 2018}} He is a professor and doctoral supervisor of Sichuan University, a visiting professor of Zhejiang University and an adjunct professor at Suzhou University,{{cite web|title=关于公布江苏省第五批产业教授（兼职）|url=http://seugs.seu.edu.cn/_upload/article/files/68/60/d4d9121b48b8961e7e71bfd1d3be/4db78c04-8e19-4da6-96c6-3d9a0f60985f.pdf|website=Southeast University|access-date=Dec 28, 2017}} the chairman of the board of the Chinese Antibody Society.{{cite news|url=http://jxxy.zafu.edu.cn/info/1116/14690.htm|title=集贤大讲坛：开发出中国老百姓用得起的高质量生物药|work=Zhejiang A & F University|access-date=Apr 13, 2017}}
Biography
Yu was the vice president of Research and Development at Applied Genetic Technologies Corporation ({{nasdaq|AGTC}}) and Calydon, Inc.,{{cite book|author1=Pablo Hernáiz Driever|author2=Samuel D. Rabkin|title=Replication-competent Viruses for Cancer Therapy|url=https://books.google.com/books?id=lxGTetXmzbsC&pg=PA56|date=1 January 2001|publisher=Karger Medical and Scientific Publishers|isbn=978-3-8055-7248-4|pages=56–}} the latter was acquired by Cell Genesys, Inc. in 2001, where he worked for three years following the acquisition.{{cite news|title=directors and senior management|url=http://corpsv.etnet.com.hk/data/documents/ipo/20181018/HKEX-EPS_20181018_003296021_0.PDF|work=etnet.com|access-date=18 October 2018}} In 2011, Yu founded Innovent Biologics, and it became listed on the Main Board of the HKEX with the stock code: 01801.HK. on October 31, 2018.
Achievements in biomedicine
Yu invented and developed three "Class I" drugs in China.{{cite web|title=加快迈向新药研发大国|url=http://paper.people.com.cn/rmrbhwb/html/2019-02/20/content_1909574.htm|website=People's Daily|access-date=Feb 20, 2019}} He invented Oncorine (an oncology product),{{cite book|author=Shuren Zhang|title=Progress in Cancer Immunotherapy|url=https://books.google.com/books?id=0pBFDAAAQBAJ&pg=PA244|date=30 May 2016|publisher=Springer|isbn=978-94-017-7555-7|pages=244–}} which is the world's first oncolytic virus product;{{cite journal |pmid = 29189159|year = 2018|last1 = Liang|first1 = M.|title = Oncorine, the World First Oncolytic Virus Medicine and its Update in China|journal = Current Cancer Drug Targets|volume = 18|issue = 2|pages = 171–176|doi = 10.2174/1568009618666171129221503}} Tyvyt (generic name: sintilimab), which is the domestically developed PD-1 antibody jointly developed by Innovent Biologics and Eli Lilly and Company,{{cite news|url=https://www.asianscientist.com/2019/01/pharma/innovent-eli-lilly-sintilimab-tyvyt-hodgkins-lymphoma/|title=China Approves Tyvyt For Hodgkin's Lymphoma|date=Apr 20, 2017|work=Asian Scientist Magazine|access-date=January 9, 2019}} and the key clinical results of Tyvyt in patients with r/r cHL have been published by the Lancet Haematology.{{Cite journal | url=https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30210-2/fulltext |pmid = 30612711|year = 2019|last1 = Ansell|first1 = S. M.|title = Sintilimab: Another effective immune checkpoint inhibitor in classical Hodgkin lymphoma|journal = The Lancet. Haematology|volume = 6|issue = 1|pages = e2–e3|doi = 10.1016/S2352-3026(18)30210-2| s2cid=58561198 |url-access = subscription}} And Tyvyt has been officially approved by the National Medical Products Administration{{cite web|title=治疗霍奇金淋巴瘤的PD-1抗体药物信迪利单抗注射液获批上市|url=http://www.nmpa.gov.cn/WS04/CL2056/334158.html|website=nmpa.gov.cn|access-date=28 December 2018}} for marketing in China for relapsed or refractory classical Hodgkin's lymphoma (r/r cHL) as the first approved indication.{{cite journal|title=Sintilimab: First Global Approval|journal=Drugs|volume=79|issue=3|pages=341–346|pmid=30742278|year=2019|last1=Hoy|first1=S. M.|doi=10.1007/s40265-019-1066-z|s2cid=59945274 }}
Awards and recognition
Yu Dechao was selected as "Most Influential Overseas Returnee in Life Sciences" in 2013; one of the "Top Ten Figure of Innovation in China" in 2014; "E&Y Entrepreneur of the Year in China" in 2015; "Distinguished Entrepreneur of Jiangsu Province" in 2016; national "Person of the Year in Innovation for Science and Technology in 2016" in January 2017; awarded as "The Seventh National Overseas Returnee Contributions Awards" in 2018.
References
{{reflist}}
{{Authority control}}
{{DEFAULTSORT:Yu, Dechao}}
Category:Academic staff of Sichuan University